Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas
NCT02379572 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 315
Last updated 2021-10-22
Summary
Standard treatment of glioblastomas (GBMs) consists of microsurgical resection followed by concomitant chemoradiation. The extent of resection is one of the most important prognostic factors with significant influence on the survival of patients. State of the art technique to achieve the most radical resection possible in conventional surgery is fluorescence-guidance with 5-aminolevulinic acid (5-ALA). If available, intraoperative MRI (iMRI)-guided tumor resection enables an intraoperative resection control and subsequent continuation of surgery if contrast enhancing tumor remnants are found. Therefore a more radical resection and longer survival of patients might be possible. To date no comparison of these two leading technologies for GBM-surgery is available to identify the best surgical therapy of this fatal disease and to justify significant healthcare-economic differences between both technologies.
Goal of this study is to assess the value of iMRI guidance in the resection of GBMs in comparison to conventional 5-ALA microsurgery. Primary endpoint is the number of total resections (no residual contrast enhancement) in the postoperative MRI (T1+CM within 48 hours after surgery) in each group. Secondary endpoints are perioperative clinical data, progression free survival, patients' clinical condition and overall survival.
The study design was chosen to be a parallel-group approach to compare iMRI and 5-ALA centers (n=13) to exclude possible bias which might be found by randomizing patients within individual iMRI centers and to have surgeons with the most experience possible in use of each respective technology.
Conditions
Interventions
- DEVICE
-
iMRI-guided surgery
For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.
- DRUG
-
5-ALA-guided surgery
For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
Sponsors & Collaborators
-
University Hospital Tuebingen
lead OTHER
Principal Investigators
-
Constantin Roder, Dr. · University Hospital Tuebingen, Department of Neurosurgery
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-06-30
- Primary Completion
- 2020-06-30
- Completion
- 2021-07-01
Countries
- Germany
Study Locations
More Related Trials
-
iMRI Guided Resection in Cerebral Glioma Surgery
NCT01479686 ·Status: COMPLETED ·Phase: PHASE3
-
Image Guided Therapy in the Treatment of Gliomas
NCT01263821 ·Status: TERMINATED ·Phase: NA
-
Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma
NCT00005082 ·Status: COMPLETED ·Phase: NA
-
Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study
NCT01872221 ·Status: COMPLETED ·Phase: NA
-
Physiological MRI for Precision Radiotherapy IDH-wildtype Glioblastoma
NCT05970757 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
NCT06090903 ·Status: RECRUITING ·Phase: NA
-
Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma
NCT02540135 ·Status: WITHDRAWN ·Phase: NA
-
Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas
NCT06455189 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
NCT00274755 ·Status: COMPLETED ·Phase: PHASE2
-
Automatic Segmentation MRI Cerebral Glioma
NCT04674579 ·Status: UNKNOWN
-
Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme
NCT01252459 ·Status: UNKNOWN ·Phase: PHASE2
-
Molecular Imaging of Cancer-associated Fibroblasts in Glioblastoma: a FAPI PET/MR Study.
NCT07119294 ·Status: RECRUITING ·Phase: NA
-
Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
NCT01417507 ·Status: COMPLETED
-
Non-invasive Glioma Characterization Through Molecular Imaging
NCT03684109 ·Status: RECRUITING ·Phase: NA
-
Study About the Validity of MRS-guided Resection on Prognosis High-grade Glioma Gliomas
NCT02795364 ·Status: UNKNOWN ·Phase: NA
-
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
NCT04540107 ·Status: RECRUITING ·Phase: PHASE1
-
Image-Guided Stereotactic Biopsy of High Grade Gliomas
NCT00979810 ·Status: COMPLETED ·Phase: NA
-
Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients
NCT01089868 ·Status: COMPLETED
-
Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With Glioblastoma
NCT01880008 ·Status: COMPLETED
-
FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma
NCT01089244 ·Status: UNKNOWN
-
Glutamate Excitotoxicity and Its Role in Glioblastoma Biology
NCT05775458 ·Status: RECRUITING
-
Intraoperative Sonographically Guided Resection of Non-enhancing Gliomas
NCT05470374 ·Status: SUSPENDED ·Phase: NA
-
Mapping Molecular Markers of Brain Tumour Activity Using MRI
NCT05140785 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities
NCT00589095 ·Status: TERMINATED
-
Post-operative Imaging in High Grade Glioma: is Management Influenced?
NCT04738110 ·Status: UNKNOWN